Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Biruni University | OTHER |
| Istanbul University | OTHER |
Not provided
Not provided
Not provided
Not provided
Obesity is a growing global health problem that affects people of all ages. It can lead to serious health issues such as cardiovascular disease, insulin resistance, inflammation, and reduced physical function. New medications, including GLP-1 receptor agonists like semaglutide and dual GLP-1/GIP agonists like tirzepatide, have been shown to help people lose significant weight. However, some of this rapid weight loss may come from a reduction in muscle mass rather than fat. Losing muscle can lower physical performance, impair metabolic health, and increase the risk of developing sarcopenic obesity. This study aims to compare the effects of pharmacological treatment alone with a combined treatment program that includes both medication and exercise in individuals with obesity. The primary objective is to evaluate how these two approaches influence body composition.
The secondary objective is to examine the effects of pharmacological treatment versus combined treatment on cardiometabolic markers, peripheral muscle strength, functional capacity, respiratory function, respiratory muscle performance, and physical activity levels. The study seeks to determine whether adding structured exercise to medication can provide additional health benefits beyond weight loss.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| ARM 1-Semaglutide | Experimental | Drug: Semaglutide |
|
| ARM 3-Semaglutide + Exercise | Experimental |
| |
| ARM 4-Tirzepatide + Exercise | Experimental |
| |
| ARM 2-Tirzepatide | Experimental | Drug: Tirzepatide |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Semaglutide | Drug | They will use only semaglutide. |
| |
| Measure | Description | Time Frame |
|---|---|---|
| Body fat-muscle ratios (Body composition) | These measurements will be determined by bioelectrical impedance. | Three months |
| Measure | Description | Time Frame |
|---|---|---|
| Peripheral muscle strength | M. Quadriceps muscle strength and hand grip strength measurement will be used to evaluate peripheral muscle strength (kg). Hand-held dynamometer will be used to evaluate quadriceps muscle strength and hand grip strength (kg). | Three months |
| Glucose profile |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Safak Yigit, PhD | Contact | +905309634910 | safak.yigit@galata.edu.tr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Biruni University | Istanbul | Zeytinburnu | Turkey (Türkiye) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000591245 | semaglutide |
| D000098860 | Tirzepatide |
| ID | Term |
|---|---|
| D000067757 | Glucagon-Like Peptide-1 Receptor |
| D000067756 | Glucagon-Like Peptide Receptors |
| D043562 | Receptors, G-Protein-Coupled |
| D011956 | Receptors, Cell Surface |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Tirzepatide |
| Drug |
They will use only tirzepatide. |
|
| Tirzepatide+Exercise | Behavioral | This group will engage in exercise and receive tirzepatide therapy." |
|
| Semaglutide+Exercise | Behavioral | This group will engage in exercise and receive semaglutide therapy." |
|
Glucose profile after 12 hours of fasting will be measured. (mg/dL) |
| Three months |
| Functional capacity | Submaximal functional exercise capacity of the participants will be evaluated with the six-minute walk test. | Three months |
| Pulmonary function | Spirometric assessment will be performed to determine participants' forced expiratory volume in one second (FEV1). Spirometric assessment will be performed to determine participants' forced vital capacity (FVC). | Three months |
| Respiratory muscle strength | Respiratory muscle strength; It will be evaluated with an intraoral pressure measuring device in a sitting position. | Three months |
| Physical activity level | Step Count Measurement: Daily step count will be monitored to determine the physical activity level of the participants. Step count will be assessed with a wearable activity monitor, a portable, easy-to-use tool that can measure objectively (Huawei Watch Fit Special Edition). With its six-axis sensor, the device records the user's physical activity style information in its temporary memory throughout the duration of use. Participants will be asked to wear the activity monitor on their left wrist throughout and only remove it during bathing. After one week of use, the data recorded with the wearable activity monitor will be taken. | Three months |
| Incremental load test (Respiratory Muscle Endurance) | Respiratory muscle endurance will be evaluated by incremental load test. The incremental load test will be performed using the electronic inspiratory loading device (PowerBreathe®-KHP2). | Three months |
| Lipid Profile | Lipid profile after 12 hours of fasting will be measured | Three months |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D008565 | Membrane Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D011964 | Receptors, Gastrointestinal Hormone |
| D018000 | Receptors, Peptide |